World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Research Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 8
Page: 744-773

A COMPARATIVE STUDY OF POST-MARKETING SURVEILLANCE REQUIREMENT FOR CERIVAL CANCER MEDICINES: CDSCO VS US-FDA

Almas Shaikh*, Shoaib Syed

Shri Dhaneshwari Manav Vikas Mandal's, Dr. Vedprakash Patil Pharmacy College, Georai Tanda, Chh. Sambhajinagar – 431003.

Article Received: 22 June 2026 | | ***Article Revised: 13 July 2026*** | | ***Article Accepted: 03 July 2026***

***Corresponding Author: Almas Shaikh**
Shri Dhaneshwari Manav Vikas Mandal's, Dr. Vedprakash Patil Pharmacy College, Georai Tanda, Chh. Sambhajinagar – 431003.
DOI: https://doi.org/10.5281/zenodo.21948993

How to cite this Article: Almas Shaikh, Shoaib Syed (2026) A COMPARATIVE STUDY OF POST-MARKETING SURVEILLANCE REQUIREMENT FOR CERIVAL CANCER MEDICINES: CDSCO VS US-FDA. World Journal of Pharmaceutical Science and Research, 5(8), 744-773.

ABSTRACT

Post-Marketing Surveillance (PMS) is an essential component of pharmacovigilance that ensures the continued safety, efficacy and quality of medicines after regulatory approval. Cervical cancer medicines, including chemotherapy agents, targeted therapies, immunotherapies and HPV vaccines, require extensive monitoring due to serious adverse drug reactions and long-term safety concerns. This dissertation compares the PMS requirements and pharmacovigilance frameworks of the Central Drugs Standard Control Organization (CDSCO) and the United States Food and Drug Administration (USFDA) for cervical cancer medicines. The study evaluates the regulatory frameworks, adverse drug reaction reporting systems, PSUR/PBRER requirements, risk management systems, signal detection methods, pharmacovigilance obligations and enforcement mechanisms of both agencies. Data were collected from official regulatory guidelines, pharmacovigilance guidance documents, and published scientific literature. The findings indicate that the USFDA operates a more advanced and technology-driven pharmacovigilance system built around the FDA Adverse Event Reporting System (FAERS), MedWatch and Risk Evaluation and Mitigation Strategies (REMS), whereas CDSCO is progressively strengthening its PMS framework through the Pharmacovigilance Programme of India (PvPI) and revised requirements under the New Drugs and Clinical Trials Rules (NDCTR), 2019. The comparative analysis highlights similarities and differences in adverse event reporting timelines, periodic safety reporting obligations, signal detection capability, risk management approaches and enforcement mechanisms, and offers recommendations for strengthening the Indian pharmacovigilance system.

KEYWORDS: Post-Marketing Surveillance (PMS), pharmacovigilance, cervical cancer medicines, adverse drug reactions (ADRs), CDSCO, USFDA, Pharmacovigilance Programme of India (PvPI), FDA Adverse Event Reporting System (FAERS), Periodic Safety Update Report (PSUR), Periodic Benefit-Risk Evaluation Report (PBRER), Risk Evaluation and Mitigation Strategies (REMS), signal detection, NDCTR 2019, MedWatch, SUGAM portal, oncology pharmacovigilance, Pembrolizumab, Bevacizumab, Cisplatin, Paclitaxel, Carboplatin.

CHAPTER 1

INTRODUCTION

1.1 Background and Overview of Cervical Cancer

Cervical cancer is one of the most important public health problems affecting women worldwide and remains a leading cause of cancer-related morbidity and mortality, particularly in low- and middle-income countries. It develops from the uncontrolled growth and proliferation of abnormal cells in the cervix, which is the lower, narrow portion of the uterus that connects to the vagina. The disease usually progresses slowly over several years through a series of precancerous lesions known as cervical intraepithelial neoplasia (CIN), which, if left untreated, can eventually develop into invasive cervical carcinoma. Because the progression from precancerous changes to invasive cancer generally takes many years, cervical cancer is considered one of the most preventable and treatable forms of cancer when detected at an early stage through effective screening and timely intervention.

Globally, cervical cancer continues to pose a major burden on healthcare systems despite significant advances in preventive and therapeutic strategies. According to recent global cancer statistics, cervical cancer is among the four most common cancers affecting women worldwide. Hundreds of thousands of new cases are diagnosed annually, and a substantial proportion of affected women die from the disease each year. The burden of cervical cancer is disproportionately higher in developing and underdeveloped countries, where nearly 90% of cervical cancer-related deaths occur. Limited access to healthcare facilities, inadequate screening programmes, poor socioeconomic conditions, lack of awareness regarding preventive measures, and insufficient vaccination coverage contribute significantly to the high incidence and mortality rates observed in these regions.

India bears one of the largest burdens of cervical cancer globally. It is the second most common cancer among Indian women after breast cancer in many regions and remains one of the leading causes of cancer-related deaths among women. Every year, a large number of Indian women are diagnosed with cervical cancer, many of whom present with advanced-stage disease because of delayed diagnosis and inadequate access to regular cervical screening services. Rural populations are particularly vulnerable due to poor healthcare infrastructure, financial constraints, limited educational opportunities, social stigma, and lack of organized national screening programmers. These challenges highlight the urgent need for improved awareness campaigns, accessible screening facilities, widespread HPV vaccination programmers, and comprehensive healthcare policies aimed at reducing the burden of cervical cancer.

The primary etiological factor responsible for the development of cervical cancer is persistent infection with high-risk Human Papillomavirus (HPV). HPV is a small, non-enveloped, double-stranded DNA virus belonging to the Papillomaviridae family. More than 200 HPV genotypes have been identified, of which approximately 40 infect the anogenital tract. Among these, around 14 genotypes are classified as high-risk oncogenic types because of their strong association with malignant transformation. HPV types 16 and 18 account for nearly 70% of all cervical cancer cases worldwide, while other oncogenic types, including HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58, contribute to the remaining cases.

HPV infection is primarily transmitted through sexual contact, making it one of the most common sexually transmitted infections worldwide. Most sexually active individuals acquire HPV infection at some point during their lifetime. In the majority of cases, the infection is transient and is cleared naturally by the immune system within one to two years without causing any clinical symptoms. However, persistent infection with high-risk HPV strains can lead to integration

of viral DNA into the host genome. This integration results in continuous expression of viral oncogenes E6 and E7, which interfere with the normal function of tumour suppressor proteins p53 and retinoblastoma (Rb). The inactivation of these critical regulatory proteins leads to uncontrolled cellular proliferation, genomic instability, inhibition of apoptosis, accumulation of genetic mutations, and eventual malignant transformation of cervical epithelial cells.

Several additional risk factors increase the likelihood of persistent HPV infection and progression to cervical cancer. These include early initiation of sexual activity, multiple sexual partners, immunosuppression such as HIV infection, long-term use of oral contraceptives, cigarette smoking, multiparity, poor genital hygiene, co-infection with other sexually transmitted diseases, nutritional deficiencies, and genetic susceptibility. Socioeconomic determinants such as poverty, limited education, inadequate healthcare access, and cultural barriers further contribute to delayed diagnosis and poor treatment outcomes.

The natural history of cervical cancer involves a multistep progression beginning with HPV infection, followed by persistent viral infection, development of precancerous cervical lesions, progression to cervical intraepithelial neoplasia grades I, II and III, carcinoma in situ, and finally invasive cervical carcinoma. This gradual progression often occurs over a period of 10–20 years, providing an excellent opportunity for early detection through routine cervical screening methods. Screening techniques such as the Papanicolaou (Pap) smear, HPV DNA testing, liquid-based cytology, visual inspection with acetic acid (VIA), and colposcopic examination have significantly reduced cervical cancer incidence in countries where organized screening programmers are effectively implemented.

HPV vaccination represents one of the greatest achievements in cervical cancer prevention. Prophylactic vaccines such as the bivalent, quadrivalent and nonvalent HPV vaccines provide effective protection against high-risk HPV types responsible for the majority of cervical cancer cases. Vaccination is recommended before the onset of sexual activity, typically during adolescence, and has demonstrated excellent efficacy in preventing HPV infection, precancerous cervical lesions, and ultimately cervical cancer. Despite the proven effectiveness of HPV vaccination, coverage remains suboptimal in many developing countries due to financial constraints, vaccine hesitancy, lack of awareness, logistical challenges, and inadequate public health infrastructure.

The clinical manifestations of cervical cancer vary according to the stage of disease. Early-stage cervical cancer is frequently asymptomatic, which emphasizes the importance of regular screening. As the disease progresses, patients may present with abnormal vaginal bleeding, postcoital bleeding, intermenstrual bleeding, postmenopausal bleeding, persistent vaginal discharge, pelvic pain, dyspareunia, urinary symptoms, bowel disturbances, lower back pain, and lower limb edema resulting from lymphatic obstruction. Advanced disease may metastasize to regional lymph nodes and distant organs, including the lungs, liver, bones, and brain, resulting in significantly poorer prognosis and reduced survival.

Diagnosis of cervical cancer involves a combination of clinical examination, cytological screening, HPV testing, colposcopy-guided biopsy, histopathological evaluation, and imaging modalities such as ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT). Disease staging is performed according to the International Federation of Gynecology and Obstetrics (FIGO) staging system, which guides therapeutic decision-making and prognostic assessment.

Treatment strategies for cervical cancer depend upon several factors, including tumour stage, tumour size, histopathological subtype, lymph node involvement, patient age, reproductive wishes, overall health status, and presence of distant metastasis. Early-stage cervical cancer is primarily managed by surgery, including conization, simple hysterectomy, radical hysterectomy with pelvic lymphadenectomy, or fertility-preserving radical trachelectomy in carefully selected patients. Surgical intervention offers excellent outcomes when the disease is diagnosed at an early stage and remains confined to the cervix.

Radiotherapy constitutes another major treatment modality and plays a central role in the management of locally advanced cervical cancer. Treatment generally consists of external beam radiotherapy (EBRT) combined with intracavitary brachytherapy to achieve optimal tumour control while minimizing radiation exposure to surrounding healthy tissues. Concurrent chemoradiotherapy has become the standard treatment for locally advanced disease because chemotherapy enhances tumour radiosensitivity and improves survival outcomes.

Chemotherapy remains an essential component in the treatment of advanced, recurrent and metastatic cervical cancer. Platinum-based agents, particularly Cisplatin and Carboplatin, represent the backbone of chemotherapy regimens because of their potent DNA-damaging properties that induce apoptosis in rapidly dividing cancer cells. Paclitaxel, a microtubule-stabilizing agent, is frequently administered in combination with platinum compounds to enhance therapeutic efficacy. Other chemotherapeutic agents, including Topotecan, Gemcitabine, Ifosfamide and Vinorelbine, may also be used in selected clinical settings depending on patient characteristics and treatment response.

Recent advances in molecular oncology have led to the development of targeted therapies that selectively interfere with specific pathways involved in tumour growth and angiogenesis.

Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF), inhibits tumour angiogenesis by preventing the formation of new blood vessels required for tumour growth and metastasis. Clinical studies have demonstrated that adding Bevacizumab to platinum-based chemotherapy significantly improves overall survival and progression-free survival in patients with recurrent or metastatic cervical cancer. This has established Bevacizumab as an important component of combination therapy for advanced disease.

Immunotherapy has emerged as another significant breakthrough in cervical cancer management. Immune checkpoint inhibitors restore the body's immune response against tumour cells by blocking inhibitory pathways that suppress T-cell activation. Pembrolizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, has shown remarkable efficacy in patients with advanced or recurrent cervical cancer expressing programmed death ligand-1 (PD-L1). By enhancing the immune system's ability to recognize and destroy malignant cells, Pembrolizumab has improved treatment outcomes, prolonged survival, and offered new therapeutic options for patients with limited alternatives. Other immune checkpoint inhibitors, therapeutic vaccines, adoptive T-cell therapies, and combination immunotherapeutic approaches are currently under active clinical investigation.

Although substantial advances in surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy have significantly improved the prognosis of cervical cancer patients, these treatment modalities are associated with numerous adverse drug reactions and treatment-related toxicities. Chemotherapeutic agents commonly produce nephrotoxicity, neurotoxicity, myelosuppression, nausea, vomiting, alopecia, mucositis, fatigue, hepatotoxicity,

electrolyte disturbances, and increased susceptibility to infections. Cisplatin is particularly associated with renal toxicity, ototoxicity, peripheral neuropathy, and severe gastrointestinal adverse effects, whereas Paclitaxel commonly causes peripheral neuropathy, hypersensitivity reactions, neutropenia, and alopecia.

Similarly, targeted therapies and immunotherapies possess unique toxicity profiles. Bevacizumab may cause hypertension, proteinuria, impaired wound healing, gastrointestinal perforation, thromboembolic events, hemorrhage, and cardiovascular complications. Pembrolizumab and other immune checkpoint inhibitors may induce immune-related adverse events affecting multiple organ systems, including pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, dermatological reactions, myocarditis, and neurological complications. These immune-mediated toxicities require prompt recognition and appropriate management using immunosuppressive therapies when necessary.

Radiotherapy is also associated with both acute and late complications, including radiation cystitis, radiation proctitis, bowel dysfunction, vaginal fibrosis, sexual dysfunction, infertility, and chronic pelvic pain. Surgical procedures may result in postoperative complications such as infection, hemorrhage, urinary dysfunction, lymphocele formation, and lymphedema. Consequently, continuous pharmacovigilance, long-term follow-up, multidisciplinary patient management, individualized treatment planning, and supportive care are essential for optimizing therapeutic outcomes while minimizing treatment-related complications.

In conclusion, cervical cancer remains a major global health challenge despite being one of the most preventable forms of cancer. Persistent infection with high-risk HPV, particularly HPV-16 and HPV-18, serves as the principal causative factor, while socioeconomic inequalities, inadequate healthcare infrastructure, poor screening coverage, and limited vaccination programmes continue to contribute to its high burden in many developing nations. Advances in screening, HPV vaccination, molecular diagnostics, surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy have substantially improved patient survival and quality of life. Nevertheless, treatment-associated toxicities and adverse drug reactions necessitate careful monitoring, individualized therapeutic approaches, and comprehensive pharmacovigilance programmers. Continued efforts toward early detection, universal HPV vaccination, improved public awareness, equitable healthcare access, and development of safer and more effective therapeutic interventions are essential to reduce the global burden of cervical cancer and improve long-term patient outcomes.

1.2 Overview of Post-Marketing Surveillance and Pharmacovigilance

Post-Marketing Surveillance (PMS), also known as Phase IV pharmacovigilance, is a systematic process of monitoring the safety, efficacy, and quality of medicinal products after they have received regulatory approval and are introduced into routine clinical practice. It represents an essential component of pharmacovigilance because it ensures that medicines continue to maintain a favorable benefit-risk balance throughout their lifecycle. Although every medicine undergoes extensive preclinical testing and Phase I, II, and III clinical trials before receiving marketing authorization, these studies have several inherent limitations. Clinical trials are generally conducted on relatively small and carefully selected patient populations under controlled conditions and for limited durations. Consequently, rare adverse drug reactions (ADRs), delayed toxicities, long-term complications, drug-drug interactions, and adverse effects occurring in special populations such as elderly patients, pregnant women, children, and individuals with multiple comorbidities may remain undetected until the medicine is widely used in the general population. Therefore, continuous post-marketing monitoring is essential to identify previously unknown safety concerns and to ensure the rational and safe use of medicines.

The significance of Post-Marketing Surveillance is particularly evident in the treatment of serious diseases such as cervical cancer. Management of cervical cancer commonly involves chemotherapy, radiotherapy, targeted therapy, and immunotherapy, either alone or in combination depending on the stage and severity of the disease. Frequently used chemotherapeutic agents such as Cisplatin, Carboplatin, and Paclitaxel have significantly improved patient survival but are associated with several serious adverse effects, including nephrotoxicity, neurotoxicity, myelosuppression, hepatotoxicity, gastrointestinal disturbances, ototoxicity, and electrolyte imbalance. Similarly, targeted therapy with Bevacizumab may cause hypertension, thromboembolic events, bleeding complications, proteinuria, impaired wound healing, and gastrointestinal perforation. Immune checkpoint inhibitors such as Pembrolizumab have revolutionized cervical cancer treatment but may produce immune-related adverse events affecting multiple organ systems, including pneumonitis, hepatitis, nephritis, colitis, endocrinopathies, myocarditis, neurological disorders, and severe dermatological reactions. Since many of these adverse effects are rare or develop only after prolonged exposure, Post-Marketing Surveillance plays a crucial role in identifying these safety concerns and facilitating timely intervention.

The primary objective of PMS is to continuously evaluate the safety profile of marketed medicines and determine whether their therapeutic benefits continue to outweigh the associated risks. It aims to detect rare and previously unknown adverse drug reactions, identify changes in the frequency or severity of known adverse effects, evaluate medicine safety in special populations, assess long-term effectiveness under real-world conditions, monitor medication errors and product quality issues, and support evidence-based regulatory decision-making. PMS also contributes to improving prescribing practices, optimizing treatment guidelines, strengthening patient safety, and maintaining public confidence in medicines.

Several complementary methods are used for Post-Marketing Surveillance. The most widely utilized approach is spontaneous adverse drug reaction reporting, in which healthcare professionals, pharmaceutical companies, and patients voluntarily report suspected adverse drug reactions to national pharmacovigilance centers or regulatory authorities. These reports are collected in large safety databases and analyzed to identify possible safety signals. Although spontaneous reporting systems are inexpensive and effective for detecting rare adverse events, they often suffer from limitations such as underreporting, incomplete clinical information, reporting bias, and inability to establish definite causality.

In addition to voluntary reporting, mandatory adverse event reporting is an important legal requirement for pharmaceutical manufacturers. Marketing authorization holders are required to report serious, unexpected, or life-threatening adverse events to regulatory authorities within specified timelines. These mandatory reporting systems ensure that significant safety information becomes available promptly, allowing regulatory agencies to initiate appropriate investigations and protective measures whenever necessary. Another essential component of PMS is the preparation of Periodic Safety Update Reports (PSURs) or Periodic Benefit-Risk Evaluation Reports (PBRERs). These reports are submitted regularly by pharmaceutical companies to regulatory authorities throughout the product lifecycle. They provide comprehensive summaries of worldwide adverse event reports, cumulative safety data, scientific literature reviews, post-marketing studies, benefit-risk assessments, and proposed risk minimization measures. Careful evaluation of these reports enables regulatory agencies to determine whether modifications to prescribing information, additional clinical studies, or other regulatory actions are required.

An important scientific activity within PMS is signal detection, which refers to the identification of new or previously

unrecognized associations between a medicine and adverse events. Safety signals may arise from spontaneous reporting systems, observational studies, scientific publications, electronic health records, disease registries, or international pharmacovigilance databases. Modern pharmacovigilance increasingly employs advanced statistical methods, data mining techniques, and artificial intelligence to analyze millions of adverse event reports and rapidly identify emerging safety concerns. Once a signal is detected, detailed clinical and epidemiological investigations are performed to evaluate causality and determine the need for regulatory intervention.

Risk Management Plans (RMPs) are another important element of Post-Marketing Surveillance. An RMP outlines the known and potential risks associated with a medicine, describes pharmacovigilance activities designed to monitor these risks, and specifies measures intended to minimize patient harm. Risk minimization strategies may include educational materials for healthcare professionals, patient counselling, laboratory monitoring recommendations, restricted prescribing programmers, pregnancy prevention programmers, and controlled distribution systems. These measures help ensure that medicines are prescribed and used safely throughout their commercial life.

One of the major outcomes of effective PMS is the implementation of regulatory actions aimed at protecting public health. Regulatory authorities may revise product labeling, strengthen contraindications and warnings, modify dosage recommendations, restrict approved indications, require additional post-marketing studies, issue safety alerts to healthcare professionals, or impose controlled access programmers. In situations where the risks significantly outweigh the benefits, regulatory agencies may suspend marketing authorization or withdraw a medicine from the market. These actions ensure that newly identified safety information is rapidly communicated to healthcare providers and patients.

International collaboration plays a vital role in strengthening Post-Marketing Surveillance. The World Health Organization (WHO) coordinates the International Programme for Drug Monitoring through the Uppsala Monitoring Centre (UMC), Sweden, which maintains VigiBase, the world's largest global database of Individual Case Safety Reports (ICSRs). This programmed enables participating countries to share pharmacovigilance data, detect global safety signals, and promote harmonized regulatory decisions. Several national regulatory agencies have also established robust pharmacovigilance systems. The United States Food and Drug Administration (FDA) operates the FDA Adverse Event Reporting System (FAERS), the European Medicines Agency (EMA) manages EudraVigilance, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom administers the Yellow Card Scheme, while in India the Pharmacovigilance Programme of India (PvPI) functions under the Indian Pharmacopoeia Commission (IPC) and Central Drugs Standard Control Organization (CDSCO). PvPI collects adverse drug reaction reports through a nationwide network of Adverse Drug Reaction Monitoring Centers (AMCs), analyzes safety data, contributes reports to the WHO global database, and supports regulatory decisions to improve medicine safety in India.

Despite significant advances in pharmacovigilance, several challenges continue to affect the effectiveness of Post-Marketing Surveillance. Underreporting of adverse drug reactions remains one of the most important limitations, with only a small proportion of actual ADRs being reported. Other challenges include incomplete documentation, delayed reporting, lack of awareness among healthcare professionals and patients, variations in reporting standards across countries, limited pharmacovigilance infrastructure in developing nations, and difficulties in establishing causal relationships between medicines and adverse events. However, recent developments in electronic health records, digital reporting platforms, artificial intelligence, machine learning, and real-world evidence generation are significantly improving the efficiency and accuracy of modern pharmacovigilance systems.

In conclusion, Post-Marketing Surveillance is an indispensable component of pharmacovigilance that ensures the continued safety, efficacy, and quality of medicines after their introduction into clinical practice. By continuously monitoring adverse drug reactions, evaluating benefit-risk profiles, detecting new safety signals, implementing risk management strategies, and supporting evidence-based regulatory actions, PMS plays a critical role in safeguarding public health. Its importance is particularly pronounced in cervical cancer therapy, where chemotherapeutic agents, targeted therapies, and immunotherapies are associated with serious and potentially life-threatening adverse drug reactions requiring continuous monitoring. Strengthening pharmacovigilance systems, encouraging ADR reporting, promoting international collaboration, and adopting advanced analytical technologies will further enhance the effectiveness of Post-Marketing Surveillance and contribute to safer, more effective patient care worldwide.

1.3 Comparative Snapshot of CDSCO and USFDA

Table 1.1 provides a preliminary, at-a-glance comparison of the post-marketing surveillance and pharmacovigilance systems operated by the Central Drugs Standard Control Organization (CDSCO) in India and the United States Food and Drug Administration (USFDA), before the detailed jurisdiction-wise and comparative analysis presented in the later chapters of this dissertation.

Table 1.1: Preliminary Comparative Snapshot of CDSCO and USFDA Pharmacovigilance Systems.

Feature	CDSCO (India)	USFDA (United States)
Governing legislation	Drugs and Cosmetics Act, 1940 and Rules, 1945; New Drugs and Clinical Trials Rules (NDCTR), 2019	Federal Food, Drug, and Cosmetic (FD&C) Act; 21 CFR Part 314 (drugs) and Part 600 (biologics)
National pharmacovigilance programmed	Pharmacovigilance Programme of India (PvPI)	FDA Adverse Event Reporting System (FAERS)
Primary ADR reporting channel	ADR Monitoring Centers (AMCs) and PvPI reporting forms	MedWatch and mandatory manufacturer safety reporting
Serious ADR reporting timeline	15 days of identification	15 days for serious, unexpected ADRs
Formal risk management programmed	Limited formal Risk Management Plan (RMP) implementation	Risk Evaluation and Mitigation Strategies (REMS), mandatory when required
Signal detection approach	PvPI analysis; collaboration with WHO VigiBase	Statistical data mining, machine learning and AI-assisted analytics
Electronic reporting platform	SUGAM portal	Electronic FAERS submission

1.4 Regulatory Affairs and Pharmacovigilance

Regulatory affairs professionals play a crucial role in ensuring that medicines remain safe, effective, and compliant with regulatory requirements throughout their entire lifecycle. Their responsibilities extend beyond obtaining marketing authorization and continue throughout the post-marketing phase, where they work closely with pharmacovigilance teams to ensure that all safety-related obligations are fulfilled in accordance with national and international regulations.

As the volume of safety data generated during the post-marketing period continues to increase, regulatory affairs professionals serve as an important link between pharmaceutical companies, healthcare professionals, pharmacovigilance experts, and regulatory authorities. Their primary objective is to ensure that emerging safety information is accurately evaluated, appropriately documented, and communicated promptly to regulatory agencies, thereby safeguarding public health and maintaining the benefit-risk balance of medicinal products.

One of the major responsibilities of regulatory affairs professionals is the preparation, review, and submission of regulatory safety documents such as Periodic Safety Update Reports (PSURs) or Periodic Benefit-Risk Evaluation Reports (PBRERs). These reports provide comprehensive summaries of global safety data collected after a medicine has entered the market. They include cumulative information on adverse drug reactions, benefit-risk assessments, literature reviews, post-marketing studies, exposure data, and recommendations for risk minimization. Regulatory affairs professionals coordinate with pharmacovigilance, medical affairs, clinical research, quality assurance, and manufacturing departments to ensure that these reports are scientifically accurate, complete, and submitted within the timelines specified by regulatory authorities. Timely submission of these reports enables regulators to continuously assess the safety profile of marketed medicines and determine whether additional regulatory actions are required.

Another important responsibility is the implementation and maintenance of Risk Management Plans (RMPs) and other risk minimization measures. Regulatory affairs professionals collaborate with pharmacovigilance teams to identify known and potential safety risks associated with medicinal products and develop strategies to minimize these risks. These measures may include updating product labeling, revising package inserts, introducing new warnings and precautions, restricting approved indications, recommending laboratory monitoring, developing educational materials for healthcare professionals and patients, and implementing controlled distribution programmers when necessary. By ensuring that appropriate risk minimization measures are effectively implemented, regulatory affairs professionals contribute significantly to reducing preventable adverse drug reactions and improving patient safety.

Communication with regulatory authorities is another critical aspect of regulatory affairs. Professionals regularly interact with national and international regulatory agencies such as the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, and the Central Drugs Standard Control Organization (CDSCO) in India. They respond to regulatory queries, submit safety updates, provide supporting scientific documentation, coordinate responses to inspection findings, and ensure compliance with post-marketing commitments. Effective communication facilitates timely regulatory decision-making and strengthens the relationship between pharmaceutical companies and health authorities.

With the rapid advancement of digital technologies, pharmacovigilance systems have become increasingly technology-driven, significantly transforming the role of regulatory affairs professionals. Modern pharmacovigilance relies heavily on electronic data capture, computerized safety databases, automated signal detection, electronic case processing, and online regulatory submissions. Regulatory professionals must therefore remain proficient in electronic reporting systems, including the Electronic Common Technical Document (eCTD), Individual Case Safety Report (ICSR) submissions in ICH E2B(R3) format, electronic gateway submissions, and database management systems used for pharmacovigilance. They are responsible for ensuring that all regulatory submissions meet the required technical standards, data quality requirements, and submission timelines established by different regulatory authorities.

The increasing globalization of pharmaceutical development has also emphasized the importance of international regulatory harmonization. Organizations such as the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the World Health Organization (WHO) have developed globally accepted guidelines to standardize pharmacovigilance practices across different countries. Regulatory affairs professionals play a key role in implementing these harmonized guidelines within pharmaceutical organizations.

They ensure compliance with important ICH guidelines, including ICH E2A for clinical safety data management, ICH E2B for electronic transmission of Individual Case Safety Reports, ICH E2C for Periodic Benefit-Risk Evaluation Reports, ICH E2D for post-approval safety data management, ICH E2E for pharmacovigilance planning, and ICH E2F for Development Safety Update Reports. Compliance with these international standards facilitates consistent safety reporting, improves global information sharing, and enhances regulatory efficiency across multiple jurisdictions.

Furthermore, regulatory affairs professionals contribute significantly to regulatory intelligence by continuously monitoring changes in pharmacovigilance legislation, emerging safety guidelines, regulatory expectations, and international best practices. They evaluate the impact of new regulations on existing products and ensure that pharmaceutical companies promptly adapt their pharmacovigilance systems to maintain compliance. Regular training of internal personnel, development of standard operating procedures (SOPs), support during regulatory inspections and pharmacovigilance audits, and implementation of quality management systems are also integral aspects of their responsibilities.

In conclusion, regulatory affairs professionals serve as an essential component of modern pharmacovigilance by ensuring that all regulatory obligations related to medicine safety are fulfilled efficiently throughout the product lifecycle. Their responsibilities encompass safety reporting, preparation of periodic safety reports, implementation of risk management strategies, electronic regulatory submissions, communication with health authorities, regulatory intelligence, and compliance with international pharmacovigilance guidelines. As pharmacovigilance continues to evolve through advances in digital technologies, artificial intelligence, and global regulatory harmonization, the role of regulatory affairs professionals has become increasingly strategic in protecting public health, ensuring regulatory compliance, and promoting the safe and effective use of medicines worldwide.

1.5 Need for the Study

Post-Marketing Surveillance is an essential part of pharmacovigilance that ensures the continued safety, efficacy and quality of medicines after they are approved and marketed. Clinical trials conducted before approval are limited by small sample sizes, short study durations, restricted patient populations and controlled clinical settings, so that many rare, delayed or population-specific adverse drug reactions only become evident once medicines are used in large populations under real-world conditions. This is of particular importance for cervical cancer medicines: chemotherapeutic agents such as Cisplatin, Carboplatin and Paclitaxel are associated with nephrotoxicity, neurotoxicity, ototoxicity, bone marrow suppression and gastrointestinal toxicity; targeted agents such as Bevacizumab are associated with hypertension, bleeding complications, delayed wound healing, gastrointestinal perforation and thromboembolic events; and immune checkpoint inhibitors such as Pembrolizumab can produce immune-related adverse events including pneumonitis, hepatitis, endocrine disorders and severe inflammatory reactions.

Post-marketing surveillance helps regulatory authorities and healthcare professionals detect previously unknown adverse drug reactions, monitor long-term safety and effectiveness, evaluate benefit-risk balance, identify drug interactions, update prescribing information, support regulatory decision-making, and, where necessary, initiate product recalls. India has made significant progress in pharmacovigilance through the Pharmacovigilance Programme of India (PvPI), but challenges remain, including underreporting of adverse drug reactions, limited awareness among healthcare professionals, limited electronic integration, and resource and manpower constraints. Studying the more technologically advanced USFDA framework can help identify strategies, such as AI-based signal detection, stronger electronic

reporting systems, more structured risk management plans and enhanced data-mining technologies, that could be adopted to strengthen the Indian pharmacovigilance system.

1.6 Need for a Comparative Regulatory Study

Different countries follow different pharmacovigilance and post-marketing surveillance systems, and comparing major regulatory frameworks helps identify strengths, gaps and areas for improvement. This study compares the PMS requirements of the Central Drugs Standard Control Organization and the U.S. Food and Drug Administration because both agencies regulate widely used cervical cancer medicines and require adverse event reporting and post-marketing safety monitoring, yet differ substantially in regulatory maturity: the USFDA operates a highly advanced pharmacovigilance infrastructure, while CDSCO is rapidly strengthening its system through PvPI and the NDCTR, 2019. Global pharmaceutical markets are increasingly interconnected, and many cervical cancer medicines are marketed internationally, making harmonized pharmacovigilance systems and comparative regulatory understanding highly important for promoting global drug safety standards, encouraging international collaboration, and enhancing patient protection worldwide.

CHAPTER 2

REVIEW OF LITERATURE

A structured review of published literature, regulatory guidance documents and pharmacovigilance reports was undertaken to understand the current status of post-marketing surveillance for cervical cancer medicines under the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (USFDA). The literature was drawn from peer-reviewed journals, regulatory agency publications and authoritative pharmacovigilance sources. The reviews are presented below in numbered author-citation format, arranged in descending order of year of publication.

1) **Leaman S, Lu J et al. (2023)** reviewed the application of artificial intelligence (AI) in pharmacovigilance to improve post-marketing drug safety monitoring. The authors discussed the use of machine learning and natural language processing for analyzing large volumes of adverse drug reaction reports and real-world healthcare data. The study reported that AI-based tools improve the speed, accuracy, and efficiency of safety signal detection compared with conventional methods. It also highlighted the growing adoption of AI-assisted analytics by regulatory agencies such as the USFDA for signal detection and risk assessment. The review emphasized that AI supports pharmacovigilance activities but should complement, rather than replace, expert clinical evaluation. The authors concluded that AI has the potential to strengthen future pharmacovigilance systems by enabling earlier detection of emerging drug safety concerns and improving regulatory decision-making.
2) **European Medicines Agency (EMA) (2023)** The EMA's Guideline on Good Pharmacovigilance Practices (GVP) sets out the structured framework governing pharmacovigilance activities in the European regulatory system, including adverse event reporting, signal management and periodic safety reporting, and is frequently referenced as a benchmark for comparing the maturity of pharmacovigilance systems in other jurisdictions.
3) **Kalaiselvan V et al. (2019)** This paper reviews the present scenario and future challenges of pharmacovigilance in India, discussing the growth of the Pharmacovigilance Programme of India (PvPI), the expansion of ADR Monitoring Centers, and continuing challenges such as underreporting and the need for greater healthcare professional engagement.
4) **Cohen PA et al. (2019)** published a comprehensive review on cervical cancer in *The Lancet*, discussing its global

epidemiology, major risk factors, pathogenesis, diagnosis, and recent advances in treatment. The authors reported that persistent infection with high-risk Human Papillomavirus (HPV), particularly HPV-16 and HPV-18, is the primary cause of cervical cancer, with a higher disease burden in low- and middle-income countries. The review highlighted that treatment strategies have evolved from conventional surgery and chemoradiotherapy to include targeted therapies such as Bevacizumab and immunotherapies such as Pembrolizumab, which have improved survival outcomes in advanced disease. However, these newer therapies are associated with serious adverse drug reactions, including immune-related toxicities and organ-specific complications, requiring continuous safety monitoring. The authors emphasized the importance of individualized treatment selection, long-term follow-up, and careful assessment of the benefit-risk profile of anticancer medicines. This review provides an important clinical foundation for the present study by supporting the need for effective post-marketing surveillance and pharmacovigilance systems to ensure the safe use of cervical cancer medicines after marketing approval.

5) **Beninger P. (2018)** presented a comprehensive overview of modern pharmacovigilance, describing its evolution from a reactive system based mainly on spontaneous adverse drug reaction (ADR) reporting to a proactive, science-driven approach for ensuring medicine safety throughout the product lifecycle. The review emphasized the integration of structured risk management, signal detection, benefit-risk assessment, and continuous post-marketing surveillance into routine pharmacovigilance practice. The author highlighted the increasing use of real-world evidence, electronic safety databases, and advanced analytical tools to improve the early identification of potential safety risks. The study also discussed the expanding responsibilities of regulatory authorities and pharmaceutical companies in maintaining robust pharmacovigilance systems and implementing effective risk minimization measures. Furthermore, it stressed the importance of international collaboration and harmonized regulatory guidelines in strengthening global drug safety monitoring. This review provides a strong conceptual basis for the present study by emphasizing the critical role of comprehensive post-marketing surveillance in ensuring the safe and effective use of medicines, including cervical cancer therapies.

6) **Sharma A, Gupta SK. (2017)** reviewed the pharmacovigilance system in India, highlighting the regulatory framework governed by the Central Drugs Standard Control Organization (CDSCO) and the operational role of the Pharmacovigilance Programme of India (PvPI) in monitoring medicine safety. The authors described the establishment of ADR Monitoring Centers (AMCs) across the country to improve the collection and reporting of adverse drug reactions. The review emphasized that although India's pharmacovigilance system has shown considerable progress, challenges such as underreporting of ADRs, inadequate awareness among healthcare professionals, and limited pharmacovigilance infrastructure continue to affect its effectiveness. The authors recommended strengthening training programmers, improving reporting practices, and enhancing collaboration among healthcare professionals, regulatory authorities, and pharmaceutical companies. This study provides valuable insight into the current status and future needs of the Indian pharmacovigilance system, which is directly relevant to the present comparative study of CDSCO and USFDA post-marketing surveillance frameworks.

7) **Sarker A et al. (2015)** reviewed the potential of social media as an emerging source of pharmacovigilance data for identifying adverse drug reactions (ADRs). The authors discussed the application of natural language processing (NLP) techniques to extract ADR-related information from user-generated content on online platforms. The review highlighted that social media can complement conventional reporting systems such as FAERS by providing early insights into patient experiences. However, challenges including data reliability, privacy concerns, and standardization of information were also emphasized. The study concluded that social media analytics could

strengthen post-marketing surveillance when integrated with traditional pharmacovigilance systems.

8) **Gupta YK, Padhy BM. (2015)** reviewed the development and progress of the Pharmacovigilance Programme of India (PvPI) following its implementation. The authors reported improvements in adverse drug reaction reporting and the expansion of ADR Monitoring Centres across the country. Despite these advancements, they identified persistent challenges such as underreporting, inadequate awareness among healthcare professionals, and limited infrastructure. The review recommended continuous training, awareness programmers, and stronger regulatory support to improve the effectiveness of pharmacovigilance in India. This study highlights the need for further strengthening India's post-marketing surveillance system.
9) **Harpaz R et.al (2013)** evaluated various signal detection algorithms used in pharmacovigilance for identifying potential safety signals from large adverse event databases such as FAERS. The study compared disproportionality analysis methods with advanced data-mining techniques to determine their effectiveness in detecting genuine adverse drug reactions. The authors concluded that no single algorithm was universally superior and recommended combining multiple analytical approaches for improved signal detection. Their findings contributed to enhancing the scientific accuracy of pharmacovigilance activities. The study supports the use of advanced analytical methods in modern post-marketing surveillance.
10) **International Council for Harmonization (ICH) (2012)** The International Council for Harmonization (ICH) published the E2C(R2) guideline in 2012 to standardize the preparation and submission of Periodic Benefit-Risk Evaluation Reports (PBRERs) worldwide. The guideline defines the structure, content, and reporting requirements for periodic safety reports submitted by pharmaceutical companies. It emphasizes continuous evaluation of the benefit-risk profile of medicinal products throughout their lifecycle. The guideline has been adopted by many regulatory authorities, including the USFDA, and has influenced pharmacovigilance practices in several countries. It provides an internationally harmonized framework for post-marketing safety reporting.
11) **Bate A, Evans SJW. (2009)** reviewed quantitative methods used for signal detection in spontaneous adverse drug reaction reporting systems. The authors discussed disproportionality analysis techniques such as the Proportional Reporting Ratio (PRR) and Bayesian approaches used in international pharmacovigilance databases like VigiBase. The review highlighted the importance of statistical methods in identifying previously unknown drug safety signals at an early stage. It also emphasized that statistical findings should always be supported by clinical evaluation before regulatory decisions are made. The study remains an important reference for signal detection methodology in pharmacovigilance.
12) **Jose J, Rao PGM. (2006)** investigated the pattern of adverse drug reactions reported through spontaneous reporting in an Indian tertiary care teaching hospital. The study documented the frequency, severity, and types of ADRs observed among hospitalized patients and highlighted the usefulness of hospital-based pharmacovigilance programmes. The authors emphasized that spontaneous reporting plays a significant role in identifying medicine-related safety problems under routine clinical practice. They also recommended improving ADR reporting awareness among healthcare professionals. The findings provided early evidence supporting the expansion of pharmacovigilance activities in India.
13) **Waller PC, Evans SJW. (2003)** discussed the future direction of pharmacovigilance by advocating a shift from reactive adverse event reporting toward proactive benefit-risk management. The authors emphasized the importance of continuous safety monitoring throughout the entire lifecycle of medicinal products rather than relying solely on spontaneous reports. They highlighted the growing role of epidemiological studies, risk management

strategies, and systematic safety evaluations in modern pharmacovigilance. The review also encouraged closer collaboration between regulatory authorities, healthcare professionals, and the pharmaceutical industry. This paper significantly influenced the evolution of contemporary pharmacovigilance practices.

14) **Edwards IR, Aronson JK. (2000)** published a landmark review defining adverse drug reactions and their classification based on clinical characteristics and mechanisms. The authors discussed methods for identifying, diagnosing, assessing causality, and managing ADRs in clinical practice. They emphasized the importance of accurate ADR reporting for improving medicine safety and supporting regulatory decision-making. The review established standardized pharmacovigilance terminology that continues to be widely used by researchers and regulatory authorities worldwide. It remains one of the foundational references in the field of pharmacovigilance.
15) **Lazarou J, Pomeranz BH, Corey PN. (1998)** conducted a landmark meta-analysis evaluating the incidence of serious and fatal adverse drug reactions among hospitalized patients in the United States. The study demonstrated that ADRs represent a significant cause of patient morbidity and mortality despite appropriate drug use. The findings highlighted the substantial public health burden associated with adverse drug reactions and emphasized the need for effective pharmacovigilance systems. The authors concluded that improved post-marketing surveillance is essential for reducing preventable medicine-related harm. This study remains a key reference supporting the importance of drug safety monitoring.
16) **Meyboom RHB et. al. (1997)** described the fundamental principles of signal detection in pharmacovigilance using spontaneous adverse drug reaction reports. The authors explained how individual safety reports are systematically evaluated to distinguish genuine safety signals from background reporting noise. The review emphasized the importance of expert clinical judgment together with statistical evaluation in confirming potential safety concerns. It also highlighted the role of spontaneous reporting systems in identifying rare and previously unknown adverse drug reactions. This work laid the conceptual foundation for many modern signal detection methods used by regulatory authorities worldwide.

2.1 Research Gap Identified

While extensive literature exists separately on the pharmacovigilance systems of India and the United States, and on the clinical safety profile of individual cervical cancer medicines, relatively few studies provide a focused, side-by-side comparison of CDSCO and USFDA post-marketing surveillance requirements specifically in the context of cervical cancer medicines. This dissertation seeks to address that gap by systematically comparing adverse drug reaction reporting, periodic safety reporting, signal detection and risk management practices between the two agencies.

CHAPTER 3

AIM AND OBJECTIVES

3.1 Aim

The primary objective of this study is to compare the post-marketing surveillance (PMS) requirements and pharmacovigilance frameworks for cervical cancer medicines between the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (USFDA). The study aims to evaluate how both regulatory agencies monitor the safety, efficacy and risk management of cervical cancer medicines after marketing approval, and to understand the differences and similarities in adverse drug reaction reporting systems, regulatory guidelines, safety monitoring mechanisms, post-marketing commitments and pharmacovigilance practices followed by CDSCO and USFDA.

3.2 Secondary Objectives

1. To study and compare the adverse drug reaction (ADR) reporting systems used by CDSCO and USFDA.
2. To evaluate the Periodic Safety Update Report (PSUR) and Periodic Benefit-Risk Evaluation Report (PBRER) submission requirements under both regulatory authorities.
3. To analyze the pharmacovigilance frameworks, guidelines and regulatory requirements applicable to cervical cancer medicines.
4. To compare signal detection methods and safety data analysis techniques used by CDSCO and USFDA.
5. To study the role of the Pharmacovigilance Programme of India (PvPI) and the FDA Adverse Event Reporting System (FAERS) in post-marketing surveillance.
6. To evaluate risk management strategies such as Risk Evaluation and Mitigation Strategies (REMS) and other safety monitoring approaches.
7. To assess the reporting timelines and obligations for serious adverse drug reactions under both agencies.
8. To compare post-marketing study requirements and regulatory commitments for cervical cancer medicines.
9. To examine regulatory enforcement mechanisms including labelling changes, warning letters, recalls and safety alerts.
10. To identify the challenges and limitations in the Indian pharmacovigilance system and compare them with the more advanced USFDA surveillance system.
11. To suggest recommendations for improving post-marketing surveillance and pharmacovigilance practices in India.
12. To promote better patient safety, regulatory harmonisation and global pharmacovigilance collaboration in cervical cancer medicine monitoring.

CHAPTER 4

REGULATORY FRAMEWORK FOR POST-MARKETING SURVEILLANCE IN INDIA (CDSCO)

4.1 Regulatory Authority and Legal Framework

The regulatory framework for post-marketing surveillance (PMS) and pharmacovigilance in India is governed by the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare, Government of India. CDSCO is responsible for regulating the approval, manufacture, import, distribution, and safety monitoring of pharmaceutical products in India, and plays an important role in ensuring that medicines marketed in the country remain safe, effective, and of acceptable quality throughout their lifecycle. Over the years, CDSCO has strengthened its pharmacovigilance and post-marketing surveillance requirements to improve patient safety and align more closely with international regulatory standards.

The major legal provisions governing drug regulation and PMS activities in India include the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and the New Drugs and Clinical Trials Rules (NDCTR), 2019. These regulations establish the legal framework for drug approval, clinical trials, adverse event reporting, and post-marketing obligations for pharmaceutical companies and Marketing Authorization Holders (MAHs). Under NDCTR 2019, pharmaceutical manufacturers and importers are required to maintain pharmacovigilance systems for monitoring the safety of approved medicines and reporting adverse drug reactions to regulatory authorities.

A significant milestone in strengthening pharmacovigilance in India was the establishment of the Pharmacovigilance Programme of India (PvPI) in 2010 by the Ministry of Health and Family Welfare. The programmed is coordinated by the Indian Pharmacopoeia Commission (IPC), functioning as the National Coordination Centre (NCC), in collaboration

with CDSCO. PvPI operates through a nationwide network of Adverse Drug Reaction Monitoring Centers (AMCs) located in medical colleges, government hospitals, private hospitals, and other healthcare institutions. These centers collect Individual Case Safety Reports (ICSRs) submitted by healthcare professionals and patients, evaluate the reports for causality, and upload validated data into VigiFlow, an international pharmacovigilance database. The safety data are subsequently transmitted to VigiBase, the World Health Organization's global database for adverse drug reactions managed by the Uppsala Monitoring Centre (UMC), Sweden. This international collaboration enables India to contribute to global safety signal detection while also benefiting from worldwide pharmacovigilance data.

In addition to ADR reporting, CDSCO requires Marketing Authorization Holders to implement comprehensive pharmacovigilance systems that include continuous safety monitoring, preparation and submission of Periodic Safety Update Reports (PSURs), signal detection and evaluation, risk-benefit assessment, and implementation of appropriate Risk Management Plans (RMPs) whenever necessary. Pharmaceutical companies are also expected to maintain qualified pharmacovigilance personnel, establish Standard Operating Procedures (SOPs), maintain detailed safety databases, and promptly report serious or unexpected adverse events according to regulatory timelines. Based on the accumulated safety evidence, CDSCO may recommend regulatory actions such as updating prescribing information and package inserts, issuing drug safety alerts, introducing boxed warnings, restricting indications, suspending product licenses, or withdrawing medicines from the market if the benefit-risk balance becomes unfavorable. Through continuous strengthening of its regulatory framework and harmonization with international guidelines issued by organizations such as the International Council for Harmonization (ICH) and the World Health Organization (WHO), India has significantly enhanced its post-marketing surveillance system, thereby improved medicine safety and promoting the rational use of pharmaceuticals across the country.

4.2 Pharmacovigilance Programme of India (PvPI)

CDSCO conducts post-marketing surveillance primarily through the Pharmacovigilance Programme of India (PvPI), which operates through a nationwide network of Adverse Drug Reaction Monitoring Centers (AMCs) established across medical colleges, government hospitals, private hospitals, and other healthcare institutions. Healthcare professionals at these centers report suspected adverse drug reactions, which are evaluated by the National Coordination Centre (NCC) at the Indian Pharmacopoeia Commission (IPC) to identify potential safety signals, improve drug safety, and support evidence-based regulatory decision-making. The introduction of the electronic SUGAM portal has further enhanced the efficiency of regulatory submissions, licensing procedures, and adverse event reporting by providing a secure online platform for communication between pharmaceutical companies and regulatory authorities.

Despite these developments, the Indian pharmacovigilance system continues to face several challenges, including underreporting of adverse drug reactions, limited technological integration across healthcare facilities, inadequate awareness among healthcare professionals regarding ADR reporting procedures, shortage of trained pharmacovigilance personnel, and variations in reporting quality. In addition, differences in healthcare infrastructure between urban and rural regions and limited patient awareness regarding medicine safety further restrict the effectiveness of post-marketing surveillance. CDSCO continues to strengthen its regulatory framework through revised guidelines, enhanced monitoring systems, capacity-building programmers, and collaboration with international pharmacovigilance organizations such as the World Health Organization (WHO) through the global VigiBase database maintained by the Uppsala Monitoring Centre (UMC), Sweden.

Furthermore, CDSCO has undertaken several initiatives to promote a stronger culture of pharmacovigilance and improve the quality of adverse drug reaction reporting in India. Regular training workshops, awareness campaigns, continuing medical education (CME) programmers, and pharmacovigilance seminars are organized for healthcare professionals, pharmacists, nurses, and medical students to enhance their understanding of ADR reporting and patient safety. The integration of electronic reporting systems, adoption of international pharmacovigilance guidelines issued by the International Council for Harmonization (ICH), and increasing use of digital technologies for signal detection and safety data analysis have further strengthened India's post-marketing surveillance framework. These ongoing efforts are expected to improve the accuracy and timeliness of safety reporting, facilitate early detection of potential drug-related risks, and ensure that medicines marketed in India continue to meet high standards of safety, efficacy, and quality throughout their lifecycle.

4.3 Adverse Drug Reaction Reporting Requirements

In India, adverse drug reaction (ADR) reporting is coordinated by CDSCO through the Pharmacovigilance Programme of India (PvPI). ADR Monitoring Centers (AMCs) established across medical colleges, government hospitals, private hospitals, and other healthcare institutions collect reports of suspected adverse reactions from healthcare professionals and patients. These reports are assessed for completeness and causality before being forwarded to the National Coordination Centre (NCC) at the Indian Pharmacopoeia Commission (IPC). The collected data are analyzed to identify potential safety signals, evaluate the benefit-risk profile of medicines, and support evidence-based regulatory decision-making. The validated reports are also submitted to VigiBase, the World Health Organization's global database for adverse drug reactions, enabling India to contribute to international pharmacovigilance activities.

Under CDSCO requirements, serious adverse drug reactions are generally required to be reported within 15 calendar days of identification, and pharmaceutical companies are expected to maintain comprehensive internal pharmacovigilance systems along with proper documentation of medicine safety monitoring activities. Marketing Authorization Holders (MAHs) are responsible for establishing standard operating procedures (SOPs), maintaining safety databases, preparing and submitting Periodic Safety Update Reports (PSURs), conducting benefit-risk assessments, and implementing appropriate risk minimization measures whenever necessary. They must also ensure that all safety information received from healthcare professionals, patients, literature sources, and post-marketing studies is evaluated and reported in accordance with the applicable regulatory guidelines.

In addition to routine ADR reporting, CDSCO encourages continuous pharmacovigilance through awareness programmers, training initiatives, and collaboration with healthcare institutions to improve the reporting culture among medical professionals. Healthcare providers are encouraged to report all suspected adverse drug reactions, including those associated with newly approved medicines, vaccines, biological products, and herbal formulations, irrespective of whether a causal relationship has been confirmed. The information generated through these reports assists regulatory authorities in detecting new safety signals, updating prescribing information and package inserts, issuing drug safety alerts, recommending label changes, or taking regulatory actions such as restricting product use or withdrawing medicines from the market when significant safety concerns are identified. These measures collectively strengthen the post-marketing surveillance system and enhance patient safety by ensuring the continued monitoring of medicines throughout their lifecycle.

4.4 Periodic Safety Update Report (PSUR) Requirements

CDSCO requires pharmaceutical companies to submit Periodic Safety Update Reports (PSURs) for newly approved medicines to ensure continuous monitoring of drug safety after marketing authorization. PSURs are an important pharmacovigilance tool that helps regulatory authorities evaluate whether the benefit-risk profile of a medicine remains favorable during real-world clinical use. Under CDSCO guidelines, Marketing Authorization Holders (MAHs) must submit PSURs every six months during the first two years after approval and annually for the following two years.

These reports contain detailed information on adverse drug reactions, serious and unexpected adverse events, patient exposure data, scientific safety evaluations, benefit-risk assessment updates, and actions taken to improve product safety. Regulatory authorities may request additional safety data, label modifications, or risk minimization measures based on PSUR findings. The continuous review of PSURs enables CDSCO to monitor changes in the safety profile of medicines and to take timely regulatory actions whenever new or significant risks are identified.

In addition to summarizing adverse drug reaction data, PSURs provide a comprehensive evaluation of the overall safety experience of a medicinal product during the reporting period. They include information obtained from spontaneous ADR reports, published scientific literature, clinical studies, post-marketing surveillance programmers, epidemiological investigations, and safety data received from other regulatory authorities worldwide. The reports also analyze the frequency, severity, and clinical significance of adverse events, identify emerging safety signals, evaluate the effectiveness of existing risk minimization measures, and discuss any changes in the benefit-risk balance of the medicine. This systematic evaluation enables regulatory authorities to make informed decisions regarding the continued safe use of pharmaceutical products.

The preparation and submission of PSURs require close collaboration among pharmacovigilance, regulatory affairs, medical affairs, clinical research, and quality assurance departments within pharmaceutical companies. Marketing Authorization Holders are responsible for ensuring that the reports are scientifically accurate, complete, and submitted within the prescribed timelines. Based on the findings of PSUR evaluations, CDSCO may recommend updates to prescribing information, package inserts, contraindications, warnings and precautions, dosage recommendations, or monitoring requirements. In cases where significant safety concerns are identified, additional post- marketing studies, enhanced pharmacovigilance activities, restricted indications, or other regulatory measures may be implemented to safeguard public health. Thus, PSURs serve as a critical component of India's pharmacovigilance system by supporting continuous safety assessment and ensuring that marketed medicines maintain an acceptable benefit-risk profile throughout their lifecycle.

4.5 Signal Detection System

CDSCO uses multiple pharmacovigilance tools and databases for detecting potential safety signals associated with medicines. The primary system is PvPI, which collects ADR reports from ADR Monitoring Centers located across the country and evaluates them to identify unexpected or emerging safety concerns related to marketed drugs. CDSCO also collaborates with the World Health Organization through the global VigiBase database, which contains millions of ADR reports submitted by participating countries worldwide, helping Indian regulators compare national safety data with global trends. Signal detection activities involve continuous monitoring, causality assessment, trend analysis and benefit-risk evaluation; when significant safety signals are identified, CDSCO may initiate regulatory actions such as label updates, safety warnings, or restricted-use recommendations.

4.6 Risk Management Approach

CDSCO primarily focuses on pharmacovigilance activities such as ADR reporting and PSUR submission for post-marketing risk management. Compared with more structured international systems, India currently has limited formal implementation of comprehensive Risk Management Plans (RMPs), relying mainly on continuous safety monitoring through the Pharmacovigilance Programme of India (PvPI), ADR Monitoring Centers (AMCs), and post-marketing surveillance data to identify and manage medicine-related risks. Regulatory actions may include safety alerts, prescribing information updates, warning labels, product restrictions, or, in exceptional cases, suspension or withdrawal of marketing authorization when significant safety concerns are identified. In addition to these regulatory measures, CDSCO continuously evaluates emerging safety information obtained from spontaneous adverse drug reaction reports, Periodic Safety Update Reports (PSURs), published scientific literature, clinical studies, and international pharmacovigilance databases. Whenever new safety signals are detected, CDSCO conducts a scientific benefit-risk assessment in consultation with subject experts and relevant stakeholders to determine the appropriate regulatory response. Depending on the severity and clinical significance of the identified risk, the authority may require pharmaceutical companies to strengthen product labeling, revise package inserts, implement additional safety monitoring, conduct post-marketing studies, or disseminate safety communications to healthcare professionals and patients. These activities help ensure that the benefits of marketed medicines continue to outweigh their potential risks and contribute to the ongoing improvement of patient safety and public health in India.

4.7 Regulatory Enforcement Mechanisms

When safety concerns are identified through PMS activities, CDSCO can take a range of regulatory enforcement actions, including issuing warning letters to marketing authorization holders, requiring labelling changes, and, where necessary, suspending or cancelling manufacturing or marketing licenses. CDSCO inspections of manufacturing and pharmacovigilance systems support ongoing regulatory oversight.

CHAPTER 5

REGULATORY FRAMEWORK FOR POST-MARKETING SURVEILLANCE IN THE UNITED STATES (USFDA)

5.1 Regulatory Authority and Legal Framework

The U.S. Food and Drug Administration (USFDA) operates one of the most advanced and well-established post-marketing surveillance (PMS) systems in the world. The agency is responsible for ensuring the safety, efficacy, and quality of medicines marketed in the United States through strict regulatory oversight and comprehensive pharmacovigilance programmers. PMS activities are regulated under several key legal provisions, including the Federal Food, Drug, and Cosmetic (FD&C) Act, 21 CFR Part 314 for prescription drugs, and 21 CFR Part 600 for biological products.

The USFDA adopts a lifecycle approach to drug regulation, recognizing that continuous safety monitoring is essential even after a medicine has been approved for marketing. Pharmaceutical companies are required to maintain comprehensive pharmacovigilance systems to monitor the safety of their products throughout their market life. The agency continuously evaluates information received from adverse event reports, clinical studies, scientific literature, patient registries, electronic health records, and real-world evidence to identify new or emerging safety concerns. This ongoing assessment helps ensure that the benefit-risk profile of approved medicines remains favorable and allows the

USFDA to take timely regulatory actions whenever necessary to protect public health.

5.2 FDA Adverse Event Reporting System (FAERS) and MedWatch

The FDA conducts post-marketing surveillance mainly through the FDA Adverse Event Reporting System (FAERS), a large database that collects adverse event reports from healthcare professionals, consumers, and pharmaceutical companies. The MedWatch programmed facilitates voluntary reporting of adverse events and product quality issues by healthcare professionals and the public, complementing the mandatory reporting obligations placed on manufacturers. Pharmaceutical manufacturers are legally required to submit post-marketing adverse event data to the FDA, and these reporting systems assist in detecting rare or serious side effects, updating safety warnings, and ensuring ongoing pharmacovigilance of approved medicines.

In addition to FAERS and MedWatch, the USFDA utilizes advanced surveillance initiatives such as the Sentinel System, an active surveillance network that analyzes electronic healthcare data from millions of patients across the United States. The Sentinel System enables the FDA to proactively monitor the safety of marketed medicines, vaccines, and biological products by evaluating real-world data from electronic health records, insurance claims, and healthcare databases. This active surveillance approach complements spontaneous adverse event reporting by facilitating the early detection of potential safety signals, assessing the incidence of adverse events in large populations, and supporting evidence-based regulatory decision-making. The integration of both passive and active surveillance systems has significantly strengthened the FDA's ability to identify emerging drug safety concerns and implement timely measures to protect public health.

5.3 Periodic Safety Reporting Requirements

The USFDA requires periodic post-marketing safety reporting to ensure the ongoing evaluation of approved medicines. Under 21 CFR 314.80, holders of approved New Drug Applications (NDAs) are generally required to submit periodic adverse experience reports on a quarterly basis for the first three years following approval and annually thereafter, unless the FDA has specified a different reporting schedule for a particular product. These periodic reports typically include serious and unexpected adverse drug reactions, medication errors, changes in product labeling, new contraindications or warnings, global safety information from international markets, and updated benefit-risk evaluations. Manufacturers are legally obligated to monitor, document, and report post-marketing safety information to the FDA within specified timelines. The FDA carefully reviews these reports to identify emerging safety risks and determine whether regulatory actions, such as labeling revisions, boxed warnings, implementation of additional Risk Evaluation and Mitigation Strategies (REMS), post-marketing clinical studies, or product recalls, are necessary.

In addition to routine periodic safety reports, pharmaceutical manufacturers are required to submit 15-day Alert Reports for serious and unexpected adverse drug experiences that may be associated with the use of their products. These expedited reports enable the FDA to rapidly evaluate potentially significant safety concerns and initiate timely investigations when necessary. The agency also reviews safety information from scientific literature, observational studies, clinical trials, patient registries, and international regulatory authorities to supplement the data received through periodic reporting. This comprehensive approach to post-marketing safety surveillance allows the FDA to continuously reassess the benefit-risk profile of approved medicines, implement appropriate risk minimization measures, and ensure that patients and healthcare professionals receive the most current safety information for the safe and effective use of pharmaceutical products.

5.4 Signal Detection System

The USFDA uses advanced pharmacovigilance systems for post-marketing drug safety surveillance, with the FDA Adverse Event Reporting System (FAERS) serving as the primary database for storing reports of adverse events, medication errors, and product quality complaints. The FDA employs sophisticated data mining algorithms and statistical methods, including disproportionality analysis, to identify unusual reporting patterns that may indicate new safety risks. In recent years, the agency has increasingly adopted artificial intelligence (AI)-assisted signal detection technologies to enhance pharmacovigilance efficiency. Machine learning models and predictive analytics help prioritize safety signals, improve trend recognition, reduce manual workload, and support faster and more accurate regulatory decision-making.

In addition to FAERS-based signal detection, the FDA integrates information from multiple real-world data sources, including the Sentinel System, electronic health records, insurance claims databases, patient registries, published scientific literature, and international pharmacovigilance databases. Combining these diverse sources allows the agency to perform comprehensive benefit-risk assessments and validate potential safety signals before regulatory action is taken. Advanced analytical tools enable continuous monitoring of medicine safety across large and diverse patient populations, facilitating the early detection of rare or long-term adverse events that may not have been identified during pre-marketing clinical trials. This integrated, technology-driven approach has significantly strengthened the FDA's pharmacovigilance capabilities and enhanced its ability to protect public health through timely, evidence-based regulatory interventions.

5.5 Risk Evaluation and Mitigation Strategies (REMS)

One of the major strengths of the USFDA regulatory framework is the implementation of Risk Evaluation and Mitigation Strategies (REMS) for medicines associated with significant safety risks. REMS programmers are designed to ensure that the benefits of a drug continue to outweigh its risks throughout its lifecycle. Depending on the nature of the identified risk, REMS programmes may include Medication Guides for patients, communication plans for healthcare professionals, restricted distribution systems, Elements to Assure Safe Use (ETASU), and specific monitoring requirements such as laboratory investigations or certification of prescribers and healthcare facilities. These measures help ensure that high-risk medicines are prescribed, dispensed, and used appropriately, thereby minimizing preventable adverse drug reactions and improving patient safety.

Oncology medicines, given their narrow therapeutic index and severe potential adverse effects, are frequently subject to enhanced REMS-type safety measures. Anticancer drugs may require specialized prescribing practices, close monitoring for serious toxicities, patient counseling regarding potential risks, and regular assessment of treatment response and adverse events. Such risk management strategies are particularly important for targeted therapies, immunotherapies, and biologic agents that may produce serious or life-threatening toxicities requiring early detection and prompt intervention.

The FDA continuously evaluates the effectiveness of REMS programmers throughout the post-marketing period. Marketing Authorization Holders are required to periodically assess whether the implemented REMS adequately reduce the identified risks without unnecessarily restricting patient access to treatment. Based on these assessments and emerging pharmacovigilance data, the FDA may modify, strengthen, simplify, or discontinue REMS requirements as appropriate. This dynamic and evidence-based approach enables the agency to balance patient safety with timely access

to effective therapies, ensuring that medicines with significant safety concerns continue to be used under conditions that maximize their therapeutic benefits while minimizing potential risks.

5.6 Regulatory Enforcement Mechanisms

The USFDA has strong enforcement authority and can implement a range of regulatory actions when necessary, including warning letters, product recalls, boxed warnings, market withdrawal, and mandatory labelling changes. The FDA's comprehensive and technology-driven pharmacovigilance framework is widely considered a global benchmark for post-marketing surveillance and serves as a model for many regulatory agencies worldwide, including CDSCO as it continues to modernize its own PMS infrastructure.

CHAPTER 6

RESEARCH METHODOLOGY

6.1 Study Design

This study was conducted as a comparative, observational regulatory study focusing on the post-marketing surveillance (PMS) requirements for cervical cancer medicines under the regulatory frameworks of the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (USFDA). The study evaluates and compares the pharmacovigilance systems, safety monitoring requirements, adverse event reporting mechanisms, and regulatory approaches followed by both agencies for ensuring the safe use of cervical cancer medicines after marketing approval.

The study primarily involved a comprehensive review and comparative analysis of regulatory guidelines, pharmacovigilance policies, post-marketing surveillance requirements, and official regulatory documents published by CDSCO and the USFDA. Information related to adverse drug reaction (ADR) reporting, Periodic Safety Update Reports (PSURs), Risk Management Plans (RMPs), signal detection methods, post-marketing safety reporting, regulatory enforcement actions, and safety communication strategies for cervical cancer medicines was systematically collected from publicly available regulatory sources and scientific literature. The findings were then compared to identify similarities and differences in the post-marketing surveillance frameworks of both regulatory agencies, highlighting their respective strengths, limitations, and current practices. This comparative evaluation provides a better understanding of global pharmacovigilance approaches and offers insights that may contribute to strengthening post-marketing surveillance systems and improving the safety monitoring of cervical cancer medicines, particularly within the Indian regulatory framework.

6.2 Data Sources

The research methodology was primarily based on secondary data collection and a detailed review of official regulatory documents, pharmacovigilance guidelines, and scientific literature. Data were collected from multiple reliable sources, including FDA guidance documents, CDSCO guidelines, pharmacovigilance manuals, published research journals, and publications from the World Health Organization (WHO). Regulatory frameworks such as the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, the New Drugs and Clinical Trials Rules (NDCTR), 2019, the Federal Food, Drug, and Cosmetic Act, and relevant sections of the Code of Federal Regulations (21 CFR) were also reviewed for comparative analysis.

The collected information was systematically organized and analyzed using a comparative approach to evaluate the post-marketing surveillance requirements followed by CDSCO and the USFDA for cervical cancer medicines. Key regulatory parameters, including adverse drug reaction (ADR) reporting systems, Periodic Safety Update Reports (PSURs), post-marketing safety reporting requirements, signal detection methods, risk management strategies, regulatory enforcement actions, and pharmacovigilance infrastructure, were compared to identify similarities and differences between the two agencies. The findings were interpreted descriptively and presented in a structured manner to provide a comprehensive understanding of the strengths, limitations, and regulatory practices of both organizations. This methodology facilitated an evidence-based comparison of the two pharmacovigilance systems and helped identify opportunities for strengthening post-marketing surveillance practices, particularly within the Indian regulatory framework.

6.3 Parameters of Comparison

The study focused on comparing the following pharmacovigilance and post-marketing surveillance (PMS) parameters under both regulatory authorities: adverse drug reaction (ADR) reporting systems; reporting timelines for serious adverse events; Periodic Safety Update Report (PSUR) / Periodic Benefit-Risk Evaluation Report (PBRER) requirements; risk management systems; signal detection methods; post-marketing study obligations; and regulatory enforcement actions. Special attention was given to the monitoring requirements for commonly used cervical cancer medicines such as Cisplatin, Paclitaxel, Bevacizumab, and Pembrolizumab.

In addition to evaluating individual pharmacovigilance components, the study examined the overall regulatory approaches adopted by CDSCO and the USFDA in ensuring the long-term safety of these medicines after marketing approval. Particular emphasis was placed on comparing the effectiveness of safety monitoring programmers, the use of electronic adverse event reporting systems, implementation of risk minimization strategies, periodic safety evaluations, and the role of pharmacovigilance databases in identifying emerging safety signals. The study also assessed how each regulatory authority communicates newly identified safety information to healthcare professionals and the public through safety alerts, labeling updates, and regulatory advisories. This comprehensive comparison enabled the identification of best regulatory practices and highlighted areas where the Indian post-marketing surveillance system could be further strengthened by adopting selected international pharmacovigilance approaches while considering national healthcare requirements and regulatory priorities.

6.4 Scope and Limitations

The collected information was systematically analyzed and compared to identify similarities, differences, strengths and limitations within the pharmacovigilance systems of CDSCO and USFDA, and the findings were interpreted to understand the effectiveness of existing PMS frameworks and to identify opportunities for improving drug safety monitoring practices, particularly in the Indian regulatory system. As a secondary-data-based comparative regulatory study, the analysis is necessarily limited to publicly available regulatory guidance, official publications and published literature; it does not include primary data collection such as surveys of healthcare professionals or direct analysis of raw adverse event databases, and reflects the regulatory position as understood at the time of writing, noting that pharmacovigilance requirements in both jurisdictions are subject to periodic revision.

CHAPTER 7

RESULTS AND DISCUSSION: COMPARATIVE ANALYSIS

7.1 Comparative Overview of PMS Frameworks

Table 7.1 summarises the principal parameters compared between the CDSCO and USFDA post-marketing surveillance frameworks, drawing together the jurisdiction-wise detail presented in Chapters 4 and 5.

Table 7.1: Comparative Analysis of CDSCO and USFDA Post-Marketing Surveillance Requirements.

Parameter	CDSCO	USFDA
Regulatory authority	Central Drugs Standard Control Organization (CDSCO)	U.S. Food and Drug Administration (FDA)
Pharmacovigilance programmed	Pharmacovigilance Programme of India (PvPI)	FDA Adverse Event Reporting System (FAERS)
PMS governing rules	New Drugs and Clinical Trials Rules (NDCTR), 2019	21 CFR Parts 314 and 600
Adverse event reporting system	PvPI ADR reporting forms via ADR Monitoring Centers	MedWatch and mandatory manufacturer reporting
Serious ADR reporting timeline	15 days of identification	15 days for serious, unexpected ADRs
Periodic safety reporting	PSUR mandatory: 6-monthly (years 1–2), annual (years 3–4)	Periodic reports: quarterly (years 1–3), annual thereafter (21 CFR 314.80)
Electronic reporting platform	SUGAM portal	Electronic FAERS submission
Formal risk management plan	Limited implementation	REMS mandatory when required
Signal detection approach	PvPI analysis; VigiBase collaboration	Advanced statistical/AI-assisted data mining
Inspection system	CDSCO inspection	FDA inspections
Labelling changes	CDSCO approval required	FDA approval required
Enforcement mechanisms	Warning letters; license suspension/cancellation	Recalls; boxed warnings; market withdrawal

7.2 Comparative Adverse Drug Reaction Reporting Systems

Both agencies operate structured systems for capturing adverse drug reaction (ADR) reports, but differ in their institutional design and operational framework. In India, ADR reporting is coordinated by the Central Drugs Standard Control Organization (CDSCO) through the Pharmacovigilance Programme of India (PvPI), with ADR Monitoring Centers (AMCs) established across medical colleges, hospitals, and healthcare institutions collecting reports from healthcare professionals and patients. In the United States, ADR reporting is managed primarily through the FDA Adverse Event Reporting System (FAERS), MedWatch, and mandatory manufacturer safety reports, with pharmaceutical manufacturers legally required to submit post-marketing adverse event data to the U.S. Food and Drug Administration (USFDA). Both systems serve the same underlying purpose of detecting rare or serious safety signals and supporting evidence-based regulatory decision-making. However, the USFDA system benefits from a longer-established mandatory reporting framework for industry and a highly integrated electronic reporting infrastructure, whereas the Indian system relies more heavily on spontaneous reporting through a growing but still developing network of ADR Monitoring Centers.

Another notable difference between the two systems is the level of technological integration and stakeholder participation. The USFDA has established advanced electronic reporting platforms that facilitate rapid submission, processing, and analysis of adverse event reports from healthcare professionals, consumers, and pharmaceutical companies. It also incorporates active surveillance systems and real-world data sources to complement spontaneous

reporting, enabling earlier identification of emerging safety concerns. In contrast, although India's pharmacovigilance system has made significant progress through initiatives such as the SUGAM portal, VigiFlow, and the expansion of PvPI, challenges such as underreporting, variable reporting quality, limited awareness among healthcare professionals, and unequal healthcare infrastructure continue to affect the efficiency of ADR reporting. Nevertheless, continuous efforts by CDSCO and the Indian Pharmacopoeia Commission to strengthen reporting mechanisms, increase awareness, and adopt international best practices are gradually enhancing the effectiveness of India's post-marketing surveillance system and improving patient safety.

7.3 Comparative PSUR/PBRER Requirements

Both CDSCO and USFDA require periodic post-marketing safety reporting, though the specified schedules differ. Under CDSCO guidelines, Marketing Authorization Holders must submit PSURs every six months during the first two years after approval and annually for the following two years. Under 21 CFR 314.80, USFDA requires periodic adverse experience reports quarterly for the first three years following approval and annually thereafter. Figure 7.1 illustrates these two reporting schedules on a common timeline.



Figure 7.1: Comparative Periodic Safety Reporting Schedules – CDSCO vs USFDA.

7.4 Comparative Signal Detection Methods

CDSCO relies primarily on PvPI analysis of spontaneously reported ADRs from AMCs, supplemented by collaboration with the WHO's global VigiBase database maintained by the Uppsala Monitoring Centre, which allows Indian regulators to compare national safety data against global trends. USFDA, by contrast, applies sophisticated statistical data-mining methods and disproportionality analysis to the large FAERS database, and has increasingly incorporated artificial intelligence and machine-learning-assisted tools to priorities and detect safety signals more rapidly. Figure 7.2 summarises the principal building blocks of each agency's pharmacovigilance framework side by side.

Figure 7.2: Post-Marketing Surveillance Framework Components – CDSCO vs USFDA.

Framework component	CDSCO (India)	USFDA (United States)
Core database/programmed	Pharmacovigilance Programme of India (PvPI)	FDA Adverse Event Reporting System (FAERS)
Reporting channel	ADR Monitoring Centers (AMCs); SUGAM portal	MedWatch; mandatory manufacturer reporting
Periodic reporting instrument	Periodic Safety Update Report (PSUR)	Periodic Adverse Experience Report (21 CFR 314.80)
Signal detection technique	AMC-based analysis; WHO VigiBase collaboration	Disproportionality analysis; AI/machine-learning data mining
Formal risk management tool	Limited Risk Management Plan (RMP) use	Risk Evaluation and Mitigation Strategies (REMS)

7.5 Comparative Risk Management Systems

CDSCO primarily addresses post-marketing risk management through ADR reporting and PSUR submission, with limited formal implementation of comprehensive Risk Management Plans (RMPs) compared with more structured international systems. Regulatory actions typically include safety alerts, prescribing information updates, warning labels, revised package inserts, or product restrictions when significant safety concerns are identified. The USFDA, by contrast, applies structured Risk Evaluation and Mitigation Strategies (REMS) for medicines with significant safety concerns. REMS programmers may include Medication Guides, communication plans for healthcare professionals, restricted distribution systems, Elements to Assure Safe Use (ETASU), and defined monitoring requirements. For oncology medicines such as Bevacizumab and Pembrolizumab, this more formalized risk management structure enables the USFDA to implement specific, drug-tailored risk minimization measures, whereas CDSCO's approach for similar medicines continues to rely primarily on routine pharmacovigilance activities and continuous safety monitoring.

The difference in risk management strategies reflects the overall maturity and evolution of the two regulatory systems. The USFDA adopts a proactive, lifecycle-based approach in which risk management measures are designed during the drug approval process and are continuously updated based on post-marketing safety data. This allows for early identification of high-risk medicines and implementation of targeted interventions to minimize patient harm. In contrast, CDSCO follows a comparatively reactive approach, where regulatory interventions are generally initiated after safety signals emerge through ADR reports, Periodic Safety Update Reports (PSURs), or other pharmacovigilance data. Although India's pharmacovigilance framework has made significant progress through the expansion of the Pharmacovigilance Programme of India (PvPI), there remains considerable scope for strengthening structured, product-specific risk management by incorporating comprehensive RMPs, enhanced safety monitoring plans, and evidence-based risk minimization strategies. Adoption of such practices would further improve the safe use of high-risk medicines, particularly anticancer therapies, and align India's regulatory framework more closely with internationally accepted pharmacovigilance standards.

7.6 Post-Marketing Surveillance for Selected Cervical Cancer Medicines

Regardless of jurisdiction, certain cervical cancer medicines require particularly close post-marketing monitoring because of their well-characterized toxicity profiles. Table 7.2 summarises the principal post-marketing safety monitoring focus for three commonly used agents.

Table 7.2: Post-Marketing Surveillance Focus for Selected Cervical Cancer Medicines.

Medicine	Drug Class	Key Post-Marketing Monitoring Focus
Cisplatin	Platinum-based chemotherapy	Nephrotoxicity, ototoxicity and neurotoxicity; regular renal function tests, hearing assessments and neurological evaluation recommended during treatment.
Pembrolizumab	Immune checkpoint inhibitor (immunotherapy)	Immune-related adverse events including pneumonitis, hepatitis, colitis and endocrinopathies; early detection and prompt management essential to reduce severe complications.
Bevacizumab	Anti-angiogenic targeted therapy	Hypertension, bleeding episodes, thromboembolic events, delayed wound healing and gastrointestinal perforation; blood pressure monitoring and careful patient assessment required throughout therapy.

7.7 Overall Comparative Discussion

The comparative evaluation of post-marketing surveillance systems indicates that the USFDA possesses a highly developed and technologically advanced pharmacovigilance infrastructure, supported by FAERS, MedWatch, REMS and increasingly AI-assisted signal detection. CDSCO is rapidly strengthening its own pharmacovigilance framework through PvPI, the SUGAM portal, and revised requirements under the NDCTR, 2019. Both regulatory agencies converge on certain baseline expectations notably, both require serious adverse drug reaction reporting within 15 days which suggests that, at least for time-critical safety events, the two systems are not far apart in principle even where underlying infrastructure differs considerably.

The most significant divergence lies in periodic safety reporting frequency and formal risk management. USFDA's quarterly-for-three-years periodic reporting schedule is more frequent in the early post-approval period than CDSCO's six-monthly schedule, giving the USFDA more frequent structured visibility into a new medicine's safety profile during the years when unexpected risks are most likely to emerge. Similarly, USFDA's REMS framework provides a formalized, drug-specific risk minimization tool that CDSCO does not yet possess in comparably structured form; CDSCO instead relies on general pharmacovigilance monitoring, labelling updates and, where necessary, license-level enforcement action. For high-risk oncology medicines such as Pembrolizumab and Bevacizumab, this suggests an opportunity for CDSCO to consider more structured, product-specific risk management requirements in future revisions of its pharmacovigilance guidelines.

CHAPTER 8

SUMMARY, CONCLUSION AND RECOMMENDATIONS

8.1 Summary of Findings

This dissertation compared the post-marketing surveillance (PMS) and pharmacovigilance requirements of the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (USFDA) for cervical cancer medicines. The findings indicate that while both agencies require serious adverse drug reaction reporting within 15 days and share the common objective of ensuring continued medicine safety after marketing approval, the USFDA operates a more advanced and technology-driven pharmacovigilance system, using FAERS, MedWatch, AI-assisted signal detection and a formal Risk Evaluation and Mitigation Strategies (REMS) programmed, together with a more frequent periodic safety reporting schedule in the early post-approval period. CDSCO, meanwhile, continues to strengthen its own PMS framework through the Pharmacovigilance Programme of India (PvPI), the SUGAM electronic portal, and revised PSUR requirements under the New Drugs and Clinical Trials Rules (NDCTR), 2019.

8.2 CONCLUSION

Both CDSCO and USFDA recognize post-marketing surveillance as essential for ensuring the long-term safety and effectiveness of cervical cancer medicines. The USFDA has established a highly advanced pharmacovigilance system supported by FAERS, REMS programmers and sophisticated signal detection technologies, while CDSCO has made significant progress through PvPI and strengthened regulatory frameworks under the NDCTR guidelines. Despite these improvements, CDSCO continues to face challenges such as underreporting of adverse drug reactions, limited digital integration, and resource constraints. Future improvements should focus on enhancing electronic ADR reporting systems, increasing awareness among healthcare professionals, strengthening signal detection capabilities, and improving global harmonization with International Council for Harmonization (ICH) pharmacovigilance guidelines.

8.3 Recommendations

- CDSCO should adopt AI-based signal detection systems to improve early identification of adverse drug reactions and strengthen pharmacovigilance efficiency; advanced data analytics can support faster and more accurate safety assessments.
- India should consider implementing structured, REMS-like risk management programmers for high-risk medicines, including cervical cancer therapies such as Bevacizumab and Pembrolizumab, to ensure safer prescribing, dispensing and patient monitoring practices.
- Comprehensive training programmers should be provided to healthcare professionals to improve adverse drug reaction reporting quality and pharmacovigilance awareness.
- Public awareness regarding ADR reporting should be increased through educational campaigns, digital reporting platforms and patient engagement initiatives to reduce underreporting.
- Greater international collaboration with organizations such as the World Health Organization, and closer adherence to International Council for Harmonization (ICH) guidelines, can enhance global pharmacovigilance practices and regulatory harmonization.
- CDSCO could consider evaluating the feasibility of a more frequent early-phase periodic safety reporting schedule for newly approved high-risk oncology medicines, more closely aligned with the USFDA's quarterly-for-three-years approach.

8.4 Scope for Future Research

Future research could extend this comparative analysis to include the European Medicines Agency (EMA) pharmacovigilance framework, providing a three-way comparison consistent with other regulatory affairs literature. Empirical studies analyzing real-world PvPI and FAERS data for cervical cancer medicines specifically could validate and extend the qualitative comparisons made in this dissertation. There is also scope for future research into the practical feasibility and design of structured, REMS-equivalent risk management plans for high-risk oncology medicines within the Indian regulatory system, and into the comparative effectiveness of AI-assisted signal detection tools when applied to Indian pharmacovigilance data.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 2025.
2. U.S. Food and Drug Administration (FDA). FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. Silver Spring, MD: FDA, 2024.
3. U.S. Food and Drug Administration (FDA). Risk Evaluation and Mitigation Strategies (REMS). Silver Spring, MD: FDA, 2024.
4. Uppsala Monitoring Centre. VigiBase: The WHO Global Database of Individual Case Safety Reports. UMC; 2024.
5. U.S. Food and Drug Administration (FDA). MedWatch: The FDA Safety Information and Adverse Event Reporting Program. FDA, 2024.
6. FDA Oncology Center of Excellence. Cervical Cancer Treatment and Safety Monitoring Updates. FDA, 2024.
7. National Cancer Institute. Cervical Cancer Treatment (PDQ®)--Health Professional Version. Bethesda, MD: NCI, 2024.

8. U.S. Food and Drug Administration. Sentinel Initiative: National Electronic System for Monitoring Medical Product Safety. FDA, 2024.
9. European Medicines Agency. EudraVigilance: European Data Processing Network and Management System for Reporting and Evaluating Suspected Adverse Reactions. EMA, 2024.
10. Pharmacovigilance Programme of India (PvPI). Guidance Document for Spontaneous Adverse Drug Reaction Reporting. Indian Pharmacopoeia Commission, 2023.
11. European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP). Amsterdam: EMA, 2023.
12. U.S. Food and Drug Administration (FDA). Postmarketing Safety Reporting Requirements for Human Drug and Biological Products. FDA Guidance for Industry, 2023.
13. Leaman S, Lu J, Chmielinski KS, Benabouh A, Wojtulewicz L, McCarthy M, et al. Artificial intelligence-based pharmacovigilance systems: a review. Drug Saf., 2023; 46(5): 457--472.
14. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med, 2021; 385(20): 1856--1867.
15. American Society of Clinical Oncology (ASCO). Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy. J Clin Oncol, 2021; 39(36): 4073--4126.
16. Central Drugs Standard Control Organization (CDSCO). New Drugs and Clinical Trials Rules, 2019. New Delhi: Ministry of Health and Family Welfare, Government of India, 2019.
17. Kalaiselvan V, Srivastava S, Singh A, Gupta SK. Pharmacovigilance in India: present scenario and future challenges. Drug Saf., 2019; 42(3): 339--346.
18. U.S. Food and Drug Administration (FDA). Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff. Silver Spring, MD: FDA, 2019.
19. Strom BL, Kimmel SE, Hennessy S. Textbook of Pharmacoepidemiology. 3rd ed. Chichester: Wiley-Blackwell, 2019.
20. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet, 2019; 393(10167): 169--182.
21. Beninger P. Pharmacovigilance: an overview. Clin Ther, 2018; 40(12): 1991--2004.
22. Sharma A, Gupta SK. Pharmacovigilance in India: an overview. Int J Pharm Sci Res, 2017; 8(1): 1--10.
23. International Council for Harmonisation (ICH). ICH E6(R2): Good Clinical Practice. Geneva: ICH, 2016.
24. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform, 2015; 54: 202-212.
25. Gupta YK, Padhy BM. India's pharmacovigilance programme: current status and challenges. Indian J Pharmacol, 2015; 47(6): 624--628.
26. World Health Organization. WHO Pharmacovigilance Indicators: A Practical Manual for the Assessment of Pharmacovigilance Systems. Geneva: WHO, 2015.
27. Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN. Adverse drug reactions reporting culture in pharmacovigilance programme of India. Indian J Med Res, 2014; 140(4): 563--564.
28. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med, 2014; 370(8): 734-743.
29. Norén GN, Harpaz R, Bate A, Edwards IR. Statistical signaldetectionin pharmacovigilance. In: Mann's Pharmacovigilance. 3rd ed. Wiley-Blackwell, 2014.

30. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal detection algorithms. Clin Pharmacol Ther, 2013; 93(6): 539-546.
31. International Council for Harmonisation (ICH). ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). Geneva: ICH, 2012.
32. Talbot J, Aronson JK. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th ed. Chichester: Wiley-Blackwell, 2011.
33. Singh GN, Kshirsagar NA. Pharmacovigilance in India: current status and future prospects. J Pharmacol Pharmacother, 2011; 2(1): 1--3.
34. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf., 2009; 18(6): 427--436.
35. Hartigan-Go K. Pharmacovigilance and post-marketing surveillance. JMAJ., 2008; 51(5): 347--349.
36. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press, 2007.
37. Mann RD, Andrews EB. Pharmacovigilance. 2nd ed. Chichester: Wiley, 2007.
38. Jose J, Rao PGM. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res, 2006; 54(3): 226--233.
39. International Council for Harmonisation (ICH). ICH E2E Pharmacovigilance Planning. Geneva: ICH, 2004.
40. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital. BMJ, 2004; 329(7456): 15--19.
41. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf, 2003; 12(1): 17--29.
42. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf, 2003; 26(3): 159--186.
43. World Health Organization (WHO). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO, 2002.
44. van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection. Pharmacoepidemiol Drug Saf., 2002; 11(1): 3--10.
45. World Health Organization (WHO). Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre. Geneva: WHO, 2000.
46. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000; 356(9237): 1255--1259.
47. Coulter DM. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf, 2000; 9(4): 273--280.
48. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998; 279(15): 1200--1205.
49. Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ. Principles of signal detection in pharmacovigilance. Drug Saf, 1997; 16(6): 355--365.
50. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. JAMA, 1997; 277(4): 301--306.